China SXT Pharmaceuticals annual free cash flow
2017
2018
2019
2020
2021
2022
2024
2025
China SXT Pharmaceuticals Free Cash Flow (FCF) History (SXTC)
China SXT Pharmaceuticals reported −$2.3M in free cash flow for fiscal 2025, a decrease of $412,240 from the previous fiscal year, with a free cash flow margin of −134.84%.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-03-31 | −$2.3M | −$412,240 | — | −134.84% |
| 2024 | 2024-03-31 | −$1.9M | −$2.1M | — | −100.34% |
| 2022 | 2022-03-31 | $207,361 | $1.6M | — | +7.97% |
| 2021 | 2021-03-31 | −$1.4M | −$2.2M | — | −29.20% |
| 2020 | 2020-03-31 | $803,408 | $1.1M | — | +15.56% |
| 2019 | 2019-03-31 | −$296,633 | −$1.8M | — | −4.23% |
| 2018 | 2018-03-31 | $1.5M | $1.4M | +1203.41% | +21.14% |
| 2017 | 2017-03-31 | $113,866 | — | — | +2.33% |
China SXT Pharmaceuticals quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
China SXT Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$296,633 to −$2.3M, a net decrease of $2.1M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review China SXT Pharmaceuticals filings at SEC.gov ↗